PET-CT Scanning Services Market Size, Share, and Growth Forecast, 2026 - 2033

The global PET-CT scanning services market size is likely to be valued at US$21.0 billion in 2026, and is expected to reach US$31.6 billion by 2033, growing at a CAGR of 6.0% during the forecast period from 2026 to 2033, driven by rising healthcare expenditures, growing awareness about early cancer detection, supportive reimbursement frameworks in key markets, and continuous technological enhancements in scanner sensitivity and image resolution. These factors collectively underpin the market's robust expansion.

The global PET-CT scanning services market has emerged as a cornerstone of modern diagnostic imaging, combining the metabolic insights of positron emission tomography (PET) with the anatomical precision of computed tomography (CT) into a single, powerful clinical tool.

• Dominant Region: North America is projected to dominate with 39% revenue share in 2026, supported by advanced healthcare infrastructure and high procedure volumes.
• Fastest growing Region: Asia Pacific is likely to be the fastest-growing region, driven by expanding diagnostic centers, rising cancer awareness, and healthcare investments in China and India.
• Leading Service Type: Onsite PET-CT scanning services are anticipated to dominate with the 65% of share owing to their seamless integration within hospital workflows.
• Dominant Application: Oncology is projected to dominate with a 72% share, reflecting the technology's unrivaled clinical value across the cancer care continuum.

Driver - Escalating Global Cancer Burden Driving Demand for PET-CT Imaging

The rising global incidence of cancer is among the most powerful structural growth drivers for PET-CT scanning services. According to the World Health Organization (WHO), cancer remains the second leading cause of death worldwide, with approximately 20 million new cancer cases recorded in 2022 alone, a figure expected to exceed 35 million by 2050. PET-CT imaging has established itself as the gold standard for oncological assessment, enabling clinicians to identify malignant lesions, assess tumor metabolic activity, stage disease with extraordinary accuracy, and evaluate treatment response, all in a single examination session.

In the U.S., the American Cancer Society reports over 1.9 million new cancer diagnoses annually, with lung, breast, colorectal, and prostate cancers comprising the bulk of cases requiring advanced imaging support. The clinical imperative for precise staging at diagnosis, which directly guides treatment selection and determines patient outcomes, is accelerating demand for PET-CT procedures.

Reimbursement coverage by Medicare, Medicaid, and major private insurers in North America and Europe further lowers financial barriers for patients and referring physicians, bolstering scan volumes. Hospitals and standalone imaging centers are responding by expanding their PET-CT capacity through new scanner installations, fleet renewals, and mobile service extensions.

Restraint - Radiation Exposure Concerns and Regulatory Complexity

While PET-CT is a clinically invaluable tool, the inherent ionizing radiation exposure derived from both the radiotracer and the CT component raises patient safety concerns and regulatory scrutiny. Each PET-CT examination delivers an effective radiation dose of approximately 14–25 mSv, which is significantly higher than conventional CT or MRI. Although the clinical benefits typically outweigh the radiation risk for most patients, concerns are particularly pronounced in pediatric populations and in scenarios requiring repeated scanning for treatment monitoring.

Regulatory compliance across different jurisdictions adds further operational complexity. In the European Union, the Medical Device Regulation (MDR) and radiation protection directives impose rigorous quality standards and oversight requirements. In the U.S., the Nuclear Regulatory Commission (NRC) and state agencies regulate the handling and disposal of radiopharmaceuticals. Navigating these multi-layered regulatory environments requires substantial administrative resources and can delay market entry, particularly for new service providers or for providers seeking to launch mobile PET-CT units in markets with stringent transport and licensing requirements.

Opportunity - Rising Application in Neurology and Infectious Disease Diagnostics

While oncology remains the dominant application segment, the rapidly growing clinical use of PET-CT in neurology and infectious disease diagnostics represents a compelling incremental market opportunity. The recent regulatory approvals of amyloid-targeting therapies, such as lecanemab, are creating a direct clinical imperative for amyloid PET-CT imaging to guide patient selection and therapeutic monitoring, thereby substantially expanding the addressable market for neurology PET-CT services.

In infectious disease, the COVID-19 pandemic catalyzed interest in FDG-PET-CT for evaluating pulmonary inflammation, cardiovascular complications, and long COVID sequelae. PET-CT has also shown clinical utility in diagnosing fever of unknown origin, endocarditis, and bone infections, applications that are gaining traction in academic medical centers and specialty infectious disease practices.

Service Type Insights

On-site PET-CT scanning services are anticipated to dominate, with a 65% share, owing to their seamless integration into hospital workflows. This setup ensures quick access, coordinated multidisciplinary care, and optimized scheduling for high-volume patients, particularly in oncology, cardiology, and neurology diagnostics. Apollo Hospitals provides onsite PET-CT scanning integrated within its hospital infrastructure, enabling rapid imaging access, coordinated oncology care, and efficient scheduling for high patient volumes.

Mobile PET-CT scanning services are the fastest-growing sub-segment, driven by the urgent need to expand PET-CT accessibility to underserved regions, low-density population areas, and emerging markets lacking fixed imaging infrastructure. Mobile PET-CT scanning services operate mobile PET-CT units across the U.K., delivering advanced imaging directly to hospitals without permanent scanners. This approach expands access in rural and underserved areas while reducing infrastructure costs and improving patient access to timely cancer diagnostics.

Application Insights

Oncology is projected to dominate with a 72% share, driven by the technology's unrivaled clinical value across the cancer care continuum. PET-CT is deeply embedded in clinical guidelines for the management of lung cancer, lymphoma, breast cancer, melanoma, colorectal cancer, head and neck cancers, and a growing range of other malignancies. Siemens Healthineers highlights PET-CT systems such as Biograph Vision as critical tools in oncology imaging, particularly for cancer detection, staging, and treatment evaluation.

Neurology is expected to be the fastest-growing application segment due to the increasing prevalence of brain disorders such as Alzheimer's disease and Parkinson’s disease. PET-CT enables detailed assessment of brain metabolism and function, supporting early diagnosis, disease monitoring, and improved clinical decision-making in neurological care.

GE HealthCare’s Discovery MI PET/CT is used in neurology to assess brain metabolism and detect early changes associated with disorders such as Alzheimer's disease. Its high-resolution imaging supports early diagnosis and monitoring of neurodegenerative diseases, improving clinical decision-making.

North America PET-CT Scanning Services Market Trends

North America is projected to dominate, holding 39% of revenue in 2026. The U.S. market is at the forefront of integrating AI-powered image analysis, digital PET-CT platforms, and novel radiopharmaceuticals, particularly PSMA PET tracers for prostate cancer (Pylarify, approved by the FDA in 2021) and amyloid PET tracers for Alzheimer's disease, into clinical practice.

Medicare coverage for FDG-PET in approved oncological indications, including lung, esophageal, colorectal, lymphoma, melanoma, head and neck, and thyroid cancers, creates a reliable, policy-backed revenue floor for U.S. PET-CT service providers. The expansion of coverage to additional indications, including myocardial viability assessment and selected neurology applications, is progressively widening the billable scan universe. Private insurer coverage has broadly followed Medicare's lead, reducing access barriers for commercially insured patients.

Europe PET-CT Scanning Services Market Trends

Europe represents the second-largest regional market for PET-CT scanning services, with Germany, the U.K., France, Italy, and the Netherlands emerging as the leading national markets. The U.K. has developed one of the most structured and accessible PET-CT service delivery models globally, supported by NHS England's PET-CT network, a nationally commissioned imaging program that has standardized access, quality, and reporting practices across England.

Germany leads in absolute PET-CT scanner density within the European market, underpinned by robust statutory health insurance reimbursement (GKV) coverage for oncological PET-CT indications and a well-capitalized private hospital sector. France and Italy are experiencing accelerating market growth driven by national cancer control programs, an aging population, and the progressive expansion of reimbursement coverage for PET-CT beyond traditional oncology into neurology and cardiovascular indications.

Asia Pacific PET-CT Scanning Services Market Trends

Asia Pacific is likely to be the fastest-growing regional market, driven by rapid expansion of healthcare infrastructure, a massive and growing cancer burden, rising disposable incomes, and proactive government investment in advanced diagnostic imaging capabilities. China and Japan represent the two largest national markets within the region, followed by India, Australia, and South Korea.

China's PET-CT market is experiencing transformative growth, driven by the government's Healthy China 2030 national strategy, which prioritizes early cancer detection, modernizing healthcare infrastructure, and expanding medical imaging capacity in tier-2 and tier-3 cities. The National Medical Products Administration (NMPA) has expedited approvals for new radiopharmaceuticals and PET-CT scanners, reducing the time-to-market for novel imaging agents.

Japan possesses one of the highest per-capita PET-CT scanner densities globally, reflecting the country's strong cultural and institutional emphasis on preventive health screening. Japan's widespread deployment of PET-CT in health screening programs beyond therapeutic applications positions it uniquely as a market where healthy individuals undergo PET-CT as part of annual executive health checks, generating substantial scan volumes independent of cancer referrals.

The global PET-CT scanning services market exhibits a moderately consolidated competitive structure, with a blend of large multinational imaging networks, vertically integrated healthcare groups, hospital-based service providers, and regional specialists competing for market share. Leading players are differentiated by geographic footprint, scanner fleet size, technology partnerships, and the depth of their radiopharmaceutical supply chain relationships.

Service providers are deepening partnerships with scanner manufacturers, primarily Siemens Healthineers, GE HealthCare, and Canon Medical Systems, to secure preferential access to next-generation digital PET-CT platforms and AI-powered image analysis software. These partnerships enable service centers to offer cutting-edge imaging capabilities that differentiate their referral proposition and support premium pricing.

Key Industry Developments

• In August 2025, EMC Healthcare marked a major milestone with the launch of the Biograph Vision Quadra at EMC Grha Kedoya Hospital, introducing Asia’s first whole-body PET/CT system. The hospital enabled high-speed, high-resolution full-body imaging, supporting earlier and more accurate cancer detection while improving patient comfort.
• In May 2025, Mahajan Imaging & Labs launched North India’s first AI-powered 128-slice digital PET-CT scanner in Gurugram, enhancing cancer diagnostics with faster imaging, higher resolution, and reduced radiation exposure. The company integrated the system with advanced pathology services to enable early and accurate disease detection.